Latest Safety News

WA1 Resources has announced a substantial upgrade to its Luni niobium deposit with a significant Indicated Mineral Resource Estimate and successful ferroniobium production testwork, positioning the West Arunta Project as a key player in the critical minerals sector.

Aquirian Limited has secured $5 million in fresh capital to upgrade its Wubin emulsion facility and accelerate commercialization of its innovative Collar Keeper® technology, alongside a new $1.5 million tolling contract.

Finder Energy has opened a new office in Dili to support its KTJ oil fields project, signalling a strategic push to embed local operations and partnerships in Timor-Leste.

Oceania Healthcare’s CEO delivered a confident first AGM address highlighting robust sales growth, operational efficiencies, and a refreshed strategic vision focused on care quality and sustainability.

Oceania Healthcare has modernized its property portfolio and updated its dividend policy to align with a new strategic direction under CEO Suzanne Dvorak, aiming to meet New Zealand's growing aged care demand.

NeuroScientific Biopharmaceuticals has completed its acquisition of StemSmart stem cell technology, setting the stage for a focused clinical push in treating fistulising Crohn’s disease. The company also refreshed its board and raised $7.5 million to support this next phase.

PYC Therapeutics has announced promising pre-clinical results for its RNA-based drug candidate PYC-002, targeting the genetic root of Phelan-McDermid Syndrome, with clinical trials expected to begin in 2026.

Percheron Therapeutics has licensed HMBD-002, a promising immuno-oncology monoclonal antibody targeting VISTA, from Hummingbird Bioscience, marking a strategic pivot after recent setbacks. The company plans to initiate phase II trials in 2026, aiming to advance this novel cancer therapy toward commercialisation.

Paradigm Biopharmaceuticals has acquired Proteobioactives, securing global rights to an oral combination therapy targeting early-stage osteoarthritis in humans and animals, complementing its injectable PPS phase 3 program.

GenusPlus Group has upgraded its FY2025 EBITDA guidance following strong quarterly results and acquisitions, while securing a significant $20 million rail infrastructure contract through its recent acquisition MGC Solutions.

Brightstar Resources has announced maiden Ore Reserves for its Second Fortune and Fish underground mines, underpinning FY26 production under a key Ore Purchase Agreement with Genesis Minerals. The company also signals significant exploration upside and an imminent Definitive Feasibility Study that could expand its footprint in the WA Goldfields.

Astron Corporation has received the Victorian Government's final regulatory green light for its Donald Rare Earths and Mineral Sands Project, paving the way for construction and financing. This milestone advances a strategically vital project aimed at supplying critical minerals for clean energy and defense.